HRP20220998T1 - Derivat karboksamida i njegovi dijastereoizomeri u stabilnom kristalnom obliku - Google Patents

Derivat karboksamida i njegovi dijastereoizomeri u stabilnom kristalnom obliku Download PDF

Info

Publication number
HRP20220998T1
HRP20220998T1 HRP20220998TT HRP20220998T HRP20220998T1 HR P20220998 T1 HRP20220998 T1 HR P20220998T1 HR P20220998T T HRP20220998T T HR P20220998TT HR P20220998 T HRP20220998 T HR P20220998T HR P20220998 T1 HRP20220998 T1 HR P20220998T1
Authority
HR
Croatia
Prior art keywords
carboxamide
cyanophenyl
pyrazol
propan
pyrazole
Prior art date
Application number
HRP20220998TT
Other languages
English (en)
Croatian (hr)
Inventor
Olli Törmäkangas
Terhi HEIKKINEN
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55349869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20220998(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of HRP20220998T1 publication Critical patent/HRP20220998T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20220998TT 2015-01-30 2016-01-28 Derivat karboksamida i njegovi dijastereoizomeri u stabilnom kristalnom obliku HRP20220998T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20150033 2015-01-30
EP16704029.4A EP3250554B1 (en) 2015-01-30 2016-01-28 A carboxamide derivative and its diastereomers in stable crystalline form
PCT/FI2016/050054 WO2016120530A1 (en) 2015-01-30 2016-01-28 A carboxamide derivative and its diastereomers in stable crystalline form

Publications (1)

Publication Number Publication Date
HRP20220998T1 true HRP20220998T1 (hr) 2022-11-11

Family

ID=55349869

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220998TT HRP20220998T1 (hr) 2015-01-30 2016-01-28 Derivat karboksamida i njegovi dijastereoizomeri u stabilnom kristalnom obliku

Country Status (14)

Country Link
US (4) US10010530B2 (enExample)
EP (1) EP3250554B1 (enExample)
JP (2) JP7283861B2 (enExample)
CY (1) CY1125482T1 (enExample)
DK (1) DK3250554T3 (enExample)
ES (1) ES2917549T3 (enExample)
HR (1) HRP20220998T1 (enExample)
HU (1) HUE058986T2 (enExample)
LT (1) LT3250554T (enExample)
PL (1) PL3250554T3 (enExample)
PT (1) PT3250554T (enExample)
RS (1) RS63477B1 (enExample)
SI (1) SI3250554T1 (enExample)
WO (1) WO2016120530A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641851B (zh) * 2016-08-26 2022-09-02 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途
CN108218908A (zh) * 2016-12-15 2018-06-29 连云港润众制药有限公司 一种新型雄激素受体拮抗剂的制备方法
FI3592732T3 (fi) 2017-03-07 2025-05-28 Orion Corp Kiteisen farmaseuttisen tuotteen valmistus
WO2019028689A1 (zh) * 2017-08-09 2019-02-14 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物
CN107602471B (zh) * 2017-09-22 2021-04-27 成都恒汇化成医药科技有限公司 一种达罗鲁胺的晶型制备方法
US20210087175A1 (en) * 2018-02-27 2021-03-25 Sandoz Ag Crystalline Form II of Darolutamide
TW202440088A (zh) * 2019-07-02 2024-10-16 芬蘭商奧利安公司 達洛魯胺之醫藥組成物
CN110590668A (zh) * 2019-07-17 2019-12-20 江苏君若医药有限公司 N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法
CN110452123B (zh) * 2019-08-30 2021-10-29 南京师范大学 一步构建c-c、c-n、c-s键的合成方法
CN111116476A (zh) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 制备抗肿瘤药物多拉米胺的方法
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
WO2022049075A1 (en) 2020-09-02 2022-03-10 Bend Research, Inc. Amorphous solid dispersion of darolutamide
WO2022144926A1 (en) * 2020-12-31 2022-07-07 Msn Laboratories Private Limited, R&D Center Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide
EP4706772A3 (en) 2022-02-28 2026-04-29 Química Sintética, S.A. Crystalline form of darolutamide
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
KR101958177B1 (ko) * 2011-04-21 2019-03-15 오리온 코포레이션 안드로겐 수용체 조절성 카복스아미드

Also Published As

Publication number Publication date
CY1125482T1 (el) 2026-02-25
WO2016120530A1 (en) 2016-08-04
JP2018503662A (ja) 2018-02-08
DK3250554T3 (da) 2022-06-27
US10383853B2 (en) 2019-08-20
PL3250554T3 (pl) 2022-09-19
US20180280354A1 (en) 2018-10-04
EP3250554A1 (en) 2017-12-06
ES2917549T3 (es) 2022-07-08
US20190321333A1 (en) 2019-10-24
US10376494B2 (en) 2019-08-13
PT3250554T (pt) 2022-06-02
EP3250554B1 (en) 2022-05-18
US20180008577A1 (en) 2018-01-11
US20180280355A1 (en) 2018-10-04
SI3250554T1 (sl) 2022-09-30
HUE058986T2 (hu) 2022-09-28
RS63477B1 (sr) 2022-08-31
US10835515B2 (en) 2020-11-17
LT3250554T (lt) 2022-06-10
JP2021020935A (ja) 2021-02-18
US10010530B2 (en) 2018-07-03
JP7283861B2 (ja) 2023-05-30

Similar Documents

Publication Publication Date Title
HRP20210507T1 (hr) Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku
HRP20211834T1 (hr) Kristalni čvrsti oblici 6-karboksi-2-(3,5-diklorfenil)benzoksazola
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
HRP20191439T1 (hr) Formulacije 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
AR059833A1 (es) Composiciones termoestables basadas en proteinas biodegradables procedimientos de preparacion y aplicaciones de las mismas
PH12018500284B1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
MX383935B (es) Amidas heterocíclicas como inhibidores de cinasa.
ME02805B (me) Inhibitori cdc7
CL2019000397A1 (es) Proceso para preparar el compuesto n-((s)-1-(3-(3-cloro -4-cianofenil)-1h-pirazol-1-il)-5-(1-hidroxi-etil)-1h-pirazol-3-carboxamida de la formula (1a).(divisional solicitud 201702491)
RU2017141763A (ru) Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида
EP3431075A4 (en) EDARAVONDARREICHUNGSFORM
MX372561B (es) Metodo para preparacion continua de cristales de metionina de alta densidad aparente.
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
HRP20241280T1 (hr) Kruti oblici rukapariba i soli rukapariba
EP3904310A4 (en) INORGANIC POWDER FOR HEAT-DISSIPTING RESIN COMPOSITION, HEAT-DISSIPTING RESIN COMPOSITION THEREOF AND METHOD FOR THE PREPARATION THEREOF
RU2015138934A (ru) Композиция для регулирования влажности окружающей среды, способ ее изготовления и ее использование для регулирования влажности окружающей среды
DK4081502T3 (da) Co-krystal af ketoprofen og dets fremstilling, farmaceutiske sammensætninger indeholdende samme og anvendelser heraf
MX369968B (es) Procedimiento para elaborar la forma cristalina a de lenalidomida.
EP3409664A4 (en) APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN THE PREPARATION OF TREATMENT AGENTS
HRP20211524T1 (hr) Sol derivata cefalosporina, kristalni kruti oblik istog i postupak za njegovu proizvodnju
MY195763A (en) A Herbicidal Composition and Process Thereof
PL3515989T3 (pl) Węglowodorowa mieszanina odpowiednia do włączenia urządzenia wymiennika ciepła
RU2014109682A (ru) Стабильный кристаллический моногидрат эпирубицина гидрохлорида и способ его получения
ECSP14013104A (es) Formulaciones farmacéuticas estabilizadas de un potente inhibidor de hcv
CN302570420S (zh) 恒温混水阀（1）